Bristol-Myers Squibb Co.
BMY
Get informed when a big investor buys or sells
+ FollowEarnings Call Q2 2026
July 30, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
12.2% downsideOvervalued by 12.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $133.37 Billion |
|---|---|
| Enterprise Value | $167.77 Billion |
| Dividend Yield | $2.51 (3.84%) |
| Earnings per Share | $3.46 |
| Beta | 0.24 |
| Outstanding Shares | 2,042,000,000 |
Return
| Return on Equity | 41.59% |
|---|---|
| Return on Assets | 10.59% |
| Return on Invested Capital | 17.75% |
Valuation & Multiples
| P/E Ratio | 14.39 |
|---|---|
| PEG | 9.39 |
| Price to Sales | 2.73 |
| Price to Book Ratio | 6.55 |
| Enterprise Value to Revenue | 3.41 |
| Enterprise Value to EBIT | 13.7 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 1.93 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0000▲ 106.84% |
|---|---|
| Total Calls | 4,300▼ 99.98% |
| Total Puts | 8,600▼ 99.96% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.69%▼ 74.51% |
|---|---|
| Total Invested | $5.51B▼ 94.37% |
| Investors Holding | 1,168▼ 1458.00% |
ESG Score
No data
About Bristol-Myers Squibb Co.
30,250 employees
CEO: Giovanni Caforio Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Relevant Senate Committees
Provides official revenue estimates and technical expertise for all tax legislation, directly influencing corporate tax structures and capital investment credits which are critical for BMY's financial planning and profitability.
Controls tax policy, which significantly impacts corporate valuations, and influences entitlement spending like Medicare, directly affecting drug pricing and reimbursement for BMY's products.
Allocates federal spending, which directly impacts funding for agencies like NIH (research) and healthcare programs (e.g., Medicare/Medicaid via HHS appropriations) that influence BMY's market and R&D landscape.
Directly regulates the FDA, which approves BMY's drugs, and the NIH, which funds critical medical research. Also impacts labor costs, making it highly relevant to BMY's core operations and market.
Oversees intellectual property rights (patents) which are fundamental to BMY's business model, and antitrust laws that are crucial for pharmaceutical M&A activities and market competition.
As a major healthcare provider, the VA is a significant customer for BMY's medicines. Funding decisions and procurement policies directly impact BMY's sales to this critical market segment.